Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)

NCT ID: NCT01450501

Last Updated: 2013-07-23

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 999 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-03-31
• Study Completion Date: 2014-03-31

Brief Summary

Q-fever is a zoonosis caused by Coxiella burnetii, an intracellular bacterium. Since the epidemic outbreak of acute Q-fever in Holland nearly 4030 people have been registered with the acute form of the disease. Knowing that only 40% of all infected people develop symptoms, the number of infected people (and potential candidates for chronic Q-fever) are much higher. Chronic Q-fever generally manifest itself after a couple of months or years after the primary infection (in 1-5% of all cases). The clinical presentation can be a life-threatening and frequently underdiagnosed disease, as endocarditis, infected aneurysm and vascular prosthesis or chronic Q-fever related to pregnancy and immunecompromised patients. That's why a screening program is started in the endemic area and trace patients with chronic Q-fever. So eventually, a greater group of patients with chronic vascular Q-fever can be described. In addition, there is still no therapeutic guideline for management of chronic Q-fever in patient with a vascular chronic Q-fever.

Patients with an aneurysm or vascular graft will be screened for chronic Q-fever. Patients with chronic Q-fever will be included in a follow-up program, in which additional research and treatment will start. The initial treatment of patients with chronic Q-fever is doxycycline and hydroxychloroquine for at least 18 months. In addition, patients will be monitored in 3-monthly controls, blood samples and imaging will be done. Parameters as complaints, titers, circulating DNA, grow of aneurysm, complications etc. will be investigated.

Ultimately, the current therapeutic guideline for management of C. burnetii will be evaluated if it can also be applied for patients with vascular chronic Q-fever.

Detailed Description

Study design:

Prospective observational survey

Domain:

Patients with an abdominal aneurysm or central vascular reconstruction in an endemic area after an outbreak of acute Q-fever.

Data collection:

In Jeroen Bosch Hospital and Bernhoven Hospital all patients with an aneurysm or central vascular reconstruction will be screened for Q-fever. Other hospitals in Holland will only check for Q-fever, if they suspect a patient of having an infected aneurysm or prosthesis.

A patient with chronic Q-fever will enter a multidisciplinary follow-up program. First, a PET/CT-scan will be provided (question; signs of an infected aneurysm/prosthesis)and chronic Q-fever endocarditis will be excluded. The patients will initially be treated with doxycycline 2 dd 100mg and plaquenil 200mg 3dd for at least 18 months. A 3-monthly follow-up will start, in which bloodsample, ultrasounds and PET/CTscan will be performed. Data will be collected in SPSS for analyses.

Definitions; Past resolved Q-fever: Any IgG phase 2 and IgG phase 1 <1:1024 Chronic Q-fever: IgG phase 1 >= 1:1024

Conditions

Chronic Q-fever; Aortic Aneurysm, Abdominal; Q Fever; Aneurysm; Vascular Graft Infection

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with vascular chronic Q-fever

All patients with chronic Q-fever and an aneurysm or vascular reconstruction

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients with an aneurysm of the abdominal aorta or iliac arteries of any size.
• Patients with a central vascular reconstruction, such as EVAR, aortic graft and bifurcation graft.

Exclusion Criteria

• Patients with a recent central vascular reconstruction (after 1-1-2010) due to a stenoses or occlusion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

Sponsor Role: collaborator

Jeroen Bosch Ziekenhuis

OTHER

Sponsor Role: lead

Responsible Party

J.C.J.P. Hagenaars

MD, PhD student, department of Surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Julia C.J.P. Hagenaars, MD

Role: PRINCIPAL_INVESTIGATOR

Jeroen Bosch Hospital

Locations

Jeroen Bosch Hospital

's-Hertogenbosch, North Brabant, Netherlands

Bernhoven Hospital

Veghel/Oss, North Brabant, Netherlands

Countries

Netherlands

Other Identifiers

50-51800-98-013

Identifier Type: -

Identifier Source: org_study_id